Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

UK

- PMLiVE

Positive trials bring Pfizer closer to new use for Xeljanz

Rheumatoid arthritis drug performs in two ulcerative colitis trials

- PMLiVE

GW ascendant as epilepsy drug clears phase III trial

Epidiolex proves effective in controlling seizures in children with Dravet syndrome

- PMLiVE

EMA starts review of Gilead’s Zydelig on ‘serious’ safety concerns

Trials of the leukaemia treatment have been halted while the investigation is underway

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

- PMLiVE

A better direction

Could behavioural science be the key to improving patient outcomes?

- PMLiVE

The new EU clinical trial lay summaries

New regulations will require both a trial summary and a lay person’s summary

The new EU clinical trial lay summaries

New regulations will require both a trial summary and a lay person’s summary

- PMLiVE

Genital herpes vaccine candidate promising in phase II

Genocea Biosciences’ GEN-003 found to reduce recurrence and transmission of the virus

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

- PMLiVE

Amgen’s roll-out of myeloma drug Kyprolis reaches UK

Company hopes to gain NICE approval later this year

- PMLiVE

Researchers say ‘neurostatins’ may ward off Alzheimer’s

Preclinical studies show bexarotene prevents nerve cell degeneration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links